Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. GWRE
10. CIEN

Go back to Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
(NASDAQ: TBPH) Delayed: 17.08 --0 (-0%)
Previous Close $17.08    52 Week High $38.92 
Open $17.26    52 Week Low $12.87 
Day High $17.26    P/E N/A 
Day Low $17.07    EPS $0.00 
Volume 160,550